A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape

Background: Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of many cancers. However, the limited population that benefits from ICI therapy makes it necessary to screen predictive biomarkers for stratifying patients. Currently, many biomarkers, such as tumor mutational bur...

Full description

Bibliographic Details
Main Authors: Bian, J. (Author), Chen, P. (Author), Lin, Y. (Author), Long, J. (Author), Sang, X. (Author), Wang, A. (Author), Wang, D. (Author), Yang, X. (Author), Zhang, H. (Author), Zhao, H. (Author), Zheng, M. (Author), Zheng, Y. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
adult
aged
Article
Biomarker
breast cancer
cancer immunotherapy
cancer inhibition
cancer prognosis
cancer staging
cancer survival
clinical study
cohort analysis
colorectal cancer
controlled study
copy number variation
cytotoxic T lymphocyte antigen 4 antibody
drug efficacy
esophagus cancer
female
gene dosage
gene mutation
genetic association
genetic risk score
genomics
glioma
head and neck cancer
high risk population
human
human cell
immune checkpoint inhibitor
Immune checkpoint inhibitor
immune response
Immune response
Immunotherapy
low risk population
major clinical study
male
melanoma
multiomics
multiple cancer
non small cell lung cancer
phenotype
prediction
prognostic assessment
propensity score
renal cell carcinoma
stomach cancer
survival analysis
treatment outcome
tumor associated leukocyte
tumor microenvironment
Tumor microenvironment
tumor mutational burden
urogenital tract cancer
validation process
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items